(Q54523359)

30 May 2018

title

Value of p16(INK4a) in the diagnosis of low-grade urothelial carcinoma of the urinary bladder in urinary cytology. (English)

1 reference

30 May 2018

author name string

Francesc Alameda

1

1 reference

30 May 2018

Nuria Juanpere

2

1 reference

30 May 2018

Lara Pijuan

3

1 reference

30 May 2018

Belen Lloveras

4

1 reference

30 May 2018

Javier Gimeno

5

1 reference

30 May 2018

Teresa Baró

6

1 reference

30 May 2018

Marta Salido

7

1 reference

30 May 2018

Sergio Serrano

8

1 reference

30 May 2018

Josep Lloreta

9

1 reference

30 May 2018

publication date

14 March 2012

1 reference

30 May 2018

published in

Cancer Cytopathology

1 reference

30 May 2018

volume

120

1 reference

30 May 2018

issue

4

1 reference

30 May 2018

page(s)

276-282

1 reference

30 May 2018

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

Bladder cancer detection using FISH (UroVysion assay).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

Accuracy of urine cytology and the significance of an atypical category.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

Is conventional urinary cytology still reliable for diagnosis of primary bladder carcinoma? Accuracy based on data linkage of a consecutive clinical series and cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

Methylation profiling of urothelial carcinoma in bladder biopsy and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

[Immunohistochemical expression of p53, p21, p16, and cyclin D1 in superficial bladder cancer. A tissue microarray study]

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Utility of fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared with urinary cytology

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

p16(INK4a) expression analysis as an ancillary tool for cytologic diagnosis of urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCY.21193

7 January 2021

Identifiers

DOI

10.1002/CNCY.21193

1 reference

30 May 2018

1 reference

30 May 2018